We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Complete Response Letter Casts Doubt on Adventrx Cancer Candidate
Complete Response Letter Casts Doubt on Adventrx Cancer Candidate
August 10, 2011
Adventrx Pharmaceuticals has received a complete response letter for its lung cancer candidate Exelbine, putting the drug’s future development in doubt.